Plant-based vaccines are real and surprisingly far along in development. The concept behind a “COVID vaccine in lettuce” is not science fiction but an extension of molecular farming, a technology that reprograms plant cells to manufacture vaccine proteins the same way a traditional bioreactor would, except the factory is a greenhouse. Researchers have already built SARS-CoV-2 virus-like particles inside plant tissue, tested a plant-derived COVID vaccine in large clinical trials, and turned freeze-dried lettuce leaves into prototype vaccine tablets that stay potent at room temperature. The science connecting salad greens to immunization is more advanced than most people realize, though significant hurdles remain before you could ever eat your way to immunity.
Getting Vaccine Genes Into Lettuce
The first step in making a plant-based vaccine is convincing a lettuce cell to produce a foreign protein, such as a piece of the SARS-CoV-2 spike protein. Scientists do this through two main approaches: transient expression and stable transformation.
Transient expression is the faster method. Researchers use a common soil bacterium called Agrobacterium tumefaciens to shuttle a gene of interest into plant leaf tissue through a process called agroinfiltration. The plant cells read the new gene and start cranking out the target protein within days. In lettuce specifically, vacuum-infiltrating leaf disks with Agrobacterium and incubating them for 72 hours produced recombinant protein at levels comparable to those achieved in commercially manufactured transgenic corn seeds.1PubMed. High-level transient expression of recombinant protein in lettuce The tradeoff is that transient expression is temporary. The plant makes the protein for a window of days, then stops.
Stable transformation takes longer to set up but creates permanent production lines. One approach targets the chloroplast, the compartment inside plant cells responsible for photosynthesis. Chloroplasts have their own small genome, and inserting a foreign gene there can yield extraordinary amounts of protein. Researchers who developed a chloroplast transformation system for lettuce reported that the modified chloroplasts expressed a marker protein at roughly 36% of the plant’s total soluble protein, a remarkably high yield.2PubMed. Efficient and stable transformation of Lactuca sativa L. cv. Cisco (lettuce) plastids Chloroplast transformation also carries a built-in safety advantage: because chloroplast DNA is inherited maternally in most crops, the transgene is far less likely to escape via pollen into wild plant populations.
Why Plant Cells Work as Delivery Vehicles
If you simply swallowed a purified vaccine protein, your stomach acid and digestive enzymes would tear it apart before your immune system ever saw it. Plant cells solve this problem through what researchers call bioencapsulation. The rigid cellulose wall surrounding each plant cell acts as a natural shield, protecting the vaccine protein as it passes through the acidic environment of the stomach. Once the plant material reaches the intestine, gut bacteria break down the cell walls and release the protein right where it needs to be: near the mucosal immune tissue lining the gut.3PubMed Central. Oral delivery of therapeutic proteins bioencapsulated in plant cells: preclinical and clinical advances
This targeted delivery is a key reason lettuce and other leafy greens are attractive vaccine platforms. You do not need to extract and purify the antigen from the plant tissue, package it in a synthetic nanoparticle, or inject it. The plant cell itself is the delivery capsule. Tests have shown that plant-derived antigens maintain their structure after exposure to digestive conditions and go on to trigger both mucosal IgA antibodies (which patrol the surfaces of your respiratory and digestive tracts) and systemic IgG antibodies (which circulate in the bloodstream).4PubMed. Plant-Based Oral Vaccines: Molecular Biotechnology Approaches Toward Functional Food-Based Immunization
The Mucosal Immune Advantage
Most conventional vaccines are injected into muscle, which is excellent at generating systemic antibodies but does relatively little to prime the immune defenses at mucosal surfaces like the lining of the nose, throat, and gut. These mucosal surfaces are exactly where respiratory viruses like SARS-CoV-2 first gain a foothold. Edible plant-based vaccines interact directly with the digestive tract lining and stimulate the gut-associated lymphoid tissue, a sprawling network of immune cells that can dispatch protective antibodies to mucosal surfaces throughout the body.5PubMed Central. A cross talk between the immunization and edible vaccine: Current challenges and future prospects
A vivid demonstration of this came from a study using duckweed, a tiny aquatic plant, to produce a vaccine against avian infectious bronchitis virus. Without any added chemical adjuvant, the duckweed-based vaccine triggered strong systemic IgG and mucosal secretory IgA responses, providing complete protection against a lethal viral challenge. When the researchers co-administered a plant-made immune-boosting protein (IL-17B) alongside the vaccine antigen, the immune response ramped up further, with significantly higher antibody levels in the blood and reduced viral loads in the airways.6PubMed Central. Duckweed-based edible vaccine confers complete protection against avian infectious bronchitis virus by inducing robust mucosal and systemic immunity That study was in poultry, not people, but it showed the principle works in a living animal with a real pathogen.
A Plant-Made COVID Vaccine That Reached Clinical Trials
The closest a plant-based vaccine has come to widespread human use for COVID-19 is Covifenz, developed by the Canadian company Medicago (which has since shut down for reasons unrelated to the vaccine’s performance). Medicago used a relative of tobacco, Nicotiana benthamiana, rather than lettuce, to produce coronavirus-like particles displaying the spike protein. The particles were extracted, purified, and combined with a chemical adjuvant (AS03) before being given as a standard injection, not as an edible product.
In a large phase 3 trial involving over 24,000 adults, the vaccine showed 69.5% efficacy against symptomatic COVID-19 across five circulating variants. Against moderate-to-severe disease, efficacy rose to about 79%. No severe COVID-19 cases occurred in the vaccinated group, and breakthrough infections in vaccinated participants carried viral loads more than a hundred times lower than in the placebo group.7PubMed Central. Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine Side effects were mostly mild to moderate and short-lived.
Immunogenicity data from a companion study added more detail. After two doses, about 98% of participants across age groups seroconverted, and their neutralizing antibody levels against the original vaccine strain reached roughly ten times those seen in people recovering from natural COVID-19 infection. Cross-reactive antibodies against the Alpha, Beta, and Delta variants held up well through at least six months, though activity against Omicron dropped substantially over the same period.8npj Vaccines. Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities The waning cross-reactivity to Omicron mirrored what happened with every other first-generation COVID vaccine and is not unique to the plant platform.
Covifenz was authorized for use in Canada in early 2022. It proved that a plant-grown antigen could perform comparably to conventional platforms in a rigorous human trial, even if the final product was an injection rather than something you ate.
Building Virus-Like Particles Inside Plants
Many plant-based vaccine strategies rely on virus-like particles, or VLPs. These are protein shells that mimic the shape and surface features of a real virus but contain no genetic material, so they cannot cause infection. To your immune system, a VLP looks enough like the real thing to mount a strong response.
Researchers have succeeded in assembling SARS-CoV-2 VLPs directly inside plant cells. One team co-expressed three key viral structural proteins (membrane, envelope, and nucleocapsid) in plants and found that the proteins self-assembled into spherical particles roughly 50 to 130 nanometers across, similar in size and shape to the actual virus.9Scientific Reports. Construction of SARS-CoV-2 virus-like particles in plant A separate group showed that when the full-length spike protein was expressed in plants, it interacted with host cell membranes to form spiky coronavirus-like particles about 75 to 100 nanometers in diameter, closely resembling the distinctive appearance of SARS-CoV-2 under electron microscopy.10PubMed Central. Plant‐based expression and characterization of SARS‐CoV‐2 virus‐like particles presenting a native spike protein
VLPs are appealing because their repetitive surface structure is exactly the kind of pattern the immune system has evolved to recognize aggressively. They tend to provoke stronger and more durable immune responses than individual soluble proteins. The fact that plants can assemble these complex multi-protein structures without specialized equipment is a significant technical achievement.
Freeze-Drying Lettuce Into Vaccine Tablets
For the “edible vaccine” vision to work in practice, you cannot ship fresh lettuce leaves around the world and expect them to contain a consistent dose of antigen. The solution is freeze-drying (lyophilization), which removes water from the plant tissue while preserving the structure of the vaccine proteins embedded inside.
A Polish research group has spent years refining this process specifically for lettuce expressing hepatitis B surface antigen. They found that freeze-dried lettuce tissue containing a very small dose of antigen, just 100 nanograms of assembled virus-like particles, could trigger both mucosal and systemic antibody responses in mice when given orally without any added adjuvant. The dried material was then compressed into tablets that maintained their antigen content for at least a year at room temperature.11PubMed Central. Low-dose oral immunization with lyophilized tissue of herbicide-resistant lettuce expressing hepatitis B surface antigen for prototype plant-derived vaccine tablet formulation
Getting the freeze-drying parameters right turned out to be critical. The team found that a specific drying profile, with primary drying at 20°C for 20 hours followed by secondary drying at 22°C for 2 hours, along with sucrose as a stabilizer, most effectively preserved the antigen’s VLP structure. The resulting powder contained up to 200 micrograms of VLPs per gram of dry weight, and animal immunization trials confirmed that the freeze-dried product was still immunogenic.12PubMed Central. Freeze-drying of plant tissue containing HBV surface antigen for the oral vaccine against hepatitis B Long-term stability was good at refrigerator temperature but degraded at higher temperatures, which means cold-chain requirements are reduced but not entirely eliminated.
Different antigens behave differently during processing. When the same group tested medium and large versions of the hepatitis B surface antigen, they found the medium-sized version was roughly 1.5 to 2 times more stable than the large version during freeze-drying and storage, a reminder that each vaccine candidate will need its own optimized protocol.13PubMed Central. Plant expression, lyophilisation and storage of HBV medium and large surface antigens for a prototype oral vaccine formulation
Why Plants Could Be Cheaper Than Bioreactors
The economics of plant-based manufacturing look compelling on paper. Conventional vaccine production typically relies on mammalian cell cultures or microbial fermentation inside stainless-steel bioreactors, facilities that can cost hundreds of millions of dollars to build and require expensive sterile media to operate. A large-scale mammalian cell facility can require capital investments approaching $600 million, whereas a functionally comparable plant molecular farming facility can be built for less than a tenth of that cost.14Process Biochemistry. Plant molecular farming as a biomanufacturing platform: From molecular design to industrial implementation
Plant systems also scale differently. Expanding a bioreactor-based facility means building bigger tanks while carefully maintaining the same fluid dynamics and nutrient distribution at every scale. Expanding a plant facility means growing more plants, a linear process that does not fundamentally change the production workflow. Plants do not need sterile fermenters or expensive growth media, and they carry minimal risk of harboring human pathogens, a persistent concern with mammalian cell lines.15PubMed Central. Molecular Farming for Immunization: Current Advances and Future Prospects in Plant-Produced Vaccines Recent life-cycle analyses have estimated that the environmental footprint of plant molecular farming is about 80% lower than that of conventional stainless-steel fermenter operations.14Process Biochemistry. Plant molecular farming as a biomanufacturing platform: From molecular design to industrial implementation
The honest caveat is that plants produce less protein per unit volume than high-density microbial or mammalian cultures. Typical yields from plant leaves translate to roughly 50 to 150 milligrams per liter equivalent, several orders of magnitude below what optimized cell cultures can achieve. But the cost per unit of protein is competitive because the infrastructure is so much cheaper to build and operate. The math favors plants most strongly in settings where you need to produce large quantities of a vaccine quickly and cannot afford the capital outlay for a traditional facility, which describes much of the developing world.
Hurdles Between the Lab and Your Plate
Despite the promise, several challenges explain why you are not currently vaccinating yourself with a salad. One of the most fundamental is dosing consistency. The amount of antigen in a given leaf varies depending on growing conditions, the age of the plant, and even the leaf’s position on the stem. For a vaccine to be approved by regulatory agencies, every dose must contain a precise, reproducible quantity of active ingredient. Freeze-drying and formulation into tablets help standardize the dose, but achieving pharmaceutical-grade consistency from living plant tissue is harder than standardizing a liquid coming out of a bioreactor.
A second concern is the risk of oral tolerance rather than immunization. The gut immune system has evolved to tolerate most of what passes through it, which is why you do not mount an immune response to every protein in your lunch. If the dose of antigen is too low or presented in the wrong context, the immune system may learn to ignore it rather than fight it, essentially the opposite of vaccination.16PubMed Central. Plant-made oral vaccines against human infectious diseases-Are we there yet? Navigating this threshold between tolerance and immunity is one of the trickiest aspects of oral vaccine design.
Regulatory frameworks present another barrier. Plant-made vaccines do not fit neatly into existing categories. They are grown in organisms regulated by agricultural agencies but are intended as pharmaceuticals regulated by drug agencies. The regulatory path requires quality standards at every stage of production and distribution, and the standards are still evolving. Overly rigid requirements designed for conventional manufacturing could inadvertently stifle the technology, while too-lax oversight could create safety gaps.17PubMed Central. Risk analysis for plant-made vaccines Developers and regulators are still working out where exactly the line should be drawn.
Engineering Plant Sugars for Human Compatibility
When plant cells manufacture a vaccine protein, they attach sugar molecules (glycans) to it as part of normal cellular processing. The problem is that plant glycan patterns differ from human ones. Some plant-specific sugar structures can trigger unwanted immune reactions in people or reduce how well the protein mimics its human viral counterpart.
This has driven a wave of glycoengineering, where researchers modify the plant’s sugar-attachment machinery to produce more human-like glycan patterns. Plants already have the basic capability to perform glycosylation, unlike bacteria, which lack this machinery entirely. Recent advances have made it possible to optimize the glycan structures on plant-made proteins to improve both their safety and their function.18PubMed Central. N-glycosylation modification of plant-derived virus-like particles: an application in vaccines Some glycoengineered plant lines can now produce proteins with sugar coatings nearly indistinguishable from those made by mammalian cells, removing one of the historical objections to plant-produced pharmaceuticals.
Beyond Lettuce and Beyond COVID
Lettuce gets much of the attention because it is eaten raw, grows quickly, and has well-developed transformation protocols, but it is far from the only crop under investigation. Tobacco relatives remain the workhorse of the field because they grow fast and produce large amounts of leaf biomass, though obviously no one plans to eat tobacco-based vaccines. Potatoes, tomatoes, rice, bananas, carrots, and the tiny aquatic plant duckweed have all been explored as production platforms. The hepatitis B vaccine work in lettuce, which demonstrated oral immune responses from freeze-dried tissue, built on earlier studies in potatoes that showed similar mucosal and systemic antibody responses.19IntechOpen. A Review on Edible Plant-Based Vaccines: History, Present and Future
The diseases being targeted extend well beyond COVID-19. Plant-based vaccine candidates have been developed or are in development for hepatitis B, norovirus, influenza, rabies, cholera, malaria, and several veterinary diseases. The veterinary market may actually be where the technology gains its first strong foothold, since regulatory requirements for animal vaccines are less stringent and the cost pressures are even more acute. A farmer vaccinating thousands of chickens cares intensely about per-dose cost, and a plant-grown oral vaccine that can be mixed into feed without refrigeration is an enormously attractive proposition. The duckweed-based poultry vaccine described earlier is a concrete example of this path forward.